Instrument Inactif

Autres langues Elekta AB (publ) Other OTC

Actions

EKTAY

US28617Y1010

Equipement et technologie médicale avancés

Autres langues

17/07	ELEKTA : Caution on Chinese reforms + company specific execution
16/07	MedTech facing a three-front squeeze
03/07	Elekta's Annual Report for 2025/26 available
17/06	Global markets live: Google, Amazon, SpaceX, Tesla, Rivian…
01/06	Global markets live: Nvidia, Tesla, Uber, Eli Lilly, BP plc…
29/05	ELEKTA : Punished for discipline, poised for a cleaner FY2026-27
29/05	Global markets live: Microsoft, Amazon, Dell, Chevron, Pfizer…
28/05	Elekta AB Reports Earnings Results for the Fourth Quarter and Full Year Ended April 30, 2026
28/05	Elekta AB Proposes Dividend for Fiscal Year 2025/26
28/05	Elekta AB Provides Earnings Guidance for the Fiscal Year 2026/2027
28/05	Elekta proposes dividend of SEK 2.40 per share for FY 2025/26
28/05	Elekta : Year-end report, May - April Report
18/05	Elekta : New research presented at ESTRO 2026 highlights advances in MR-guided radiotherapy
09/05	Elekta AB Initiates A Voluntary Class Ii Recall Involving Its Leksell Vantage Arc System
05/03	ELEKTA : Profitability improvements and beat, despite exogenous headwinds, are noteworthy
05/03	Elekta AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026
05/03	Elekta keeps full-year 2025/26 outlook
05/03	Elekta : Q3, May - January Report
25/02	Change in Elekta’s Nomination Committee for the Annual General Meeting 2026
04/02	The Royal Marsden NHS Foundation Trust Uses RaySearch Laboratories AB for Online Adaptive Treatments with Conventional C-arm Linacs
30/01	Elekta to reduce number of employees by 450
23/01	Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026
23/01	Elekta Appoints New Vice Chair
23/01	Elekta : appoints Tomas Eliasson as Vice Chair of the Board
16/01	Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear Accelerator